Atomoxetine

Preview FDA label, Northstar Rx LLC, oral, effective 2026-08-21. Full label on DailyMed

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using. Not yet reviewed by a ClinDose pharmacist.

Dosing in kidney impairment

This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.

Dosing in liver impairment

Recommended Dosage in Patients with Hepatic Impairment For patients aged 6 years of age or older with:

Severe hepatic impairment (HI) (Child-Pugh Class C), the recommended initial and target atomoxetine capsules dosage is 25% of recommended dosage in patients with normal hepatic function [see Use in Specific Populations and Clinical Pharmacology] .

Moderate HI (Child-Pugh Class B), the recommended initial and target atomoxetine capsules dosage is 50% of the recommended dosage in patients with normal hepatic function [see Use in Specific Populations and Clinical Pharmacology] .

Mild HI (Child-Pugh Class A), the recommended initial and target atomoxetine capsules dosage is the same as those with normal hepatic function.

Preparation and administration

Administration Instructions Atomoxetine may be taken with or without food. Take atomoxetine capsules whole; do not open the capsules.